Investment Thesis and Valuation
Key Drivers Royalty from Seebri / Ultibro and QVM149 (expected launch in FY20e) to peak at ÂĄ 4.86b in FY25e Majority of the potential milestones...
558 Views
Will Actinogen Ace Alzheimer's?
Alzheimer’s disease is an incurable neurodegenerative disorder that robs the affected individuals of memory, self-care and quality of life,...
424 Views
Sosei Placement - One-Year Return for Its 2015 Equity Raise Was 354%
Sosei Group Corp (4565 JP) is looking to raise US$204m by selling about 2m primary shares. Proceeds raised will be used to fund drug discovery and...
353 Views
Sosei Offering: Company History, Earnings Structure, Business Model and Use of Proceeds
On 10 Nov 2017 Sosei Group Corp (4565 JP) announced an overseas offering for 2.07m new shares (1.8m + 0.27m overallotment option). The offering...
364 Views
Mitsubishi Tanabe (4508) - Acquisition of NeuroDerm Playing to Strength, Not Weakness
The history of overseas acquisitions by Japanese drug companies is not a pretty one, as they've either overpaid for a skillset (Takeda (4502 JP)...
355 Views